SCHEDULE: Morgan Stanley Boosts Taysha Gene Therapies Stake

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 6.7% of Taysha Gene Therapies, Inc.'s common stock as of June 30, 2025.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Capital Services LLC, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Taysha Gene Therapies, Inc.
• As of June 30, 2025, Morgan Stanley beneficially owned an aggregate of 16,858,644 shares of Taysha Gene Therapies, Inc. common stock, representing 6.7% of the class.
• Morgan Stanley holds shared voting power over 16,651,747 shares and shared dispositive power over 16,858,644 shares.
• Morgan Stanley Capital Services LLC beneficially owned 14,095,143 shares, representing 5.6% of the class, with shared voting and dispositive power over these shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Taysha Gene Therapies, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or outlook. It is a factual report of an investment position.

Positives

• Significant institutional ownership by a major financial institution like Morgan Stanley can signal confidence in Taysha Gene Therapies, Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist stance, indicating a passive, supportive position.

Risks

• Intentional misstatements or omissions of fact in SEC filings constitute federal criminal violations.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Taysha Gene Therapies, Inc.'s business operations or financial performance.

Industry Context

Institutional investment in gene therapy companies like Taysha Gene Therapies reflects ongoing interest in the biotechnology sector, particularly in innovative therapeutic areas. Such investments are common as large institutions build diversified portfolios and take positions in companies with perceived growth potential.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by a large institutional investor, consistent with SEC regulations for Schedule 13G filings.
• The reported ownership percentages (6.7% and 5.6%) are significant for an institutional investor, placing Morgan Stanley among the larger shareholders of Taysha Gene Therapies, Inc.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional holdings, which can influence market perception, liquidity, and potentially investor confidence.
• Company Management: Awareness of major shareholders and their investment rationale (passive vs. activist) is important for investor relations and strategic planning.

Key Dates

Keywords

Taysha Gene Therapies, Morgan Stanley, Institutional Ownership, Schedule 13G, Common Stock, Gene Therapy, Biotechnology, SEC Filing, Beneficial Ownership